Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Peripheral Nervous System Diseases 2 Lymphoma 2 Head and Neck Neoplasms 2 Colorectal Neoplasms 2 Breast Neoplasms 2 Wilms Tumor 1 Vaso-Occlusive Crises 1 Sarcoma 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Oral Complications 1 Neurotoxicity Syndromes 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neoplasms 1 Multiple Endocrine Neoplasia Type 1 1 Malnutrition 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Extranodal NK-T-Cell 1 Lymphangioleiomyomatosis 1 Lung Neoplasms 1 Leukemia 1 Kidney Neoplasms 1 Gastrointestinal Neoplasms 1 Digestive System Neoplasms 1 Dendritic Cell Sarcoma, Interdigitating 1 Burkitt Lymphoma 1 Anemia, Sickle Cell 1

Interventions

Sirolimus 6 Everolimus 5 saracatinib 1 nintedanib 1 Urination 1 Sugars 1 Simvastatin 1 Resveratrol 1 Octreotide 1 Letrozole 1 Imatinib Mesylate 1 Hydroxychloroquine 1 Glutamine 1 Doxycycline 1 Celecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Lymphangioleiomyomatosis × Glutamine × Clear all

NCT04388371 2021-08-11

Glutamine PET Imaging in LAM

Vanderbilt University Medical Center

Phase 1 Completed

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡